INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
19 déc. 2018 08h00 HE
|
INmune Bio, Inc.
LA JOLLA, California, Dec. 19, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing treatments to reprogram the innate immune system to fight disease, announced today that...
Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03
11 déc. 2018 08h30 HE
|
INmune Bio, Inc.
Study Results Presented at San Antonio Breast Cancer Symposium 2018 LA JOLLA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company developing treatments to...
INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
07 déc. 2018 09h00 HE
|
INmune Bio, Inc.
Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing...
INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference
04 déc. 2018 08h30 HE
|
INmune Bio, Inc.
-Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness...
University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur
12 nov. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...
PROVECTUS ANNOUNCES PRESENTATION OF UPDATED RESULTS FROM PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR TREATMENT OF ADVANCED MELANOMA AT SMR 2018 CONGRESS
25 oct. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
- Single-agent adverse effect profiles of PV-10 and Keytruda were maintained - 65% overall objective response rate with 9% complete response, via RECIST 1.1 KNOXVILLE, TN, Oct. 25, 2018 ...
PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
18 sept. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
11 sept. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
10 juil. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting,...
PROVECTUS BIOPHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE 1B TRIAL OF PV-10 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
07 mai 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Data presentation planned for first half of 2019 KNOXVILLE, TN, May 07, 2018 (GLOBE NEWSWIRE) -- Provectus today announced the completion of enrollment of 24 patients...